Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats

(Downloading may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it.)

Click on image to view larger version.

FIG. 1.
FIG. 1.

Single oral doses of dapagliflozin increase urinary glucose excretion (A) and urine volume (B) in normal Sprague-Dawley rats over 24 h. □, Vehicle; ▪, dapagliflozin. Vehicle-treated rats excreted 2.5 mg/200 g body weight (BW), and rats treated with 0.01 mg/kg dapagliflozin excreted 3.7 mg/200 g body weight in A. *P < 0.01, †P < 0.0001, ‡P < 0.0005, each vs. vehicle.

This Article

  1. Diabetes vol. 57 no. 6 1723-1729